Drugs / RISOVALISIB
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04856371 | Apr 2021 → Mar 2022 | breast cancer | Haihe Biopharma Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04586335 | Sep 2020 → Feb 2023 | breast cancer, endometrial cancer, ovarian cancer, prostate cancer | Haihe Biopharma Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT03544905 | Jul 2018 → Dec 2024 | cancer | Haihe Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06975618 | Aug 2023 → Dec 2029 expected | PIK3CA-related overgrowth spectrum, vascular malformation | Haihe Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05043922 | Oct 2021 → Jul 2024 overdue | ovarian cancer | Haihe Biopharma Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RISOVALISIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4800252 ↗ |
| Known as | CYH33 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03544905 ↗ |
| Action | Inhibit | “CYH33 is a novel, highly potent and selective inhibitor of phosphatidylinositol 3-kinase α” NCT04586335 ↗ |
| Modality | Small molecule | — CHEMBL4800252 ↗ |
| Route | Oral | “CYH33, an Oral α-specific PI3K Inhibitor” NCT04586335 ↗ |